4.4 Review

Vaccines for Pseudomonas aeruginosa: a long and winding road

Journal

EXPERT REVIEW OF VACCINES
Volume 13, Issue 4, Pages 507-519

Publisher

TAYLOR & FRANCIS LTD
DOI: 10.1586/14760584.2014.890053

Keywords

alginate; Th17; vaccine; Pseudomonas aeruginosa; lipopolysaccharide; flagella; neutrophil

Categories

Funding

  1. NIH
  2. Cystic Fibrosis Foundation
  3. William F. Milton Fund of Harvard Medical School

Ask authors/readers for more resources

Despite the recognition of Pseudomonas aeruginosa as an opportunistic pathogen, no vaccine against this bacteria has come to market. This review describes the current state-of-the-art in vaccinology for this bacterium. This includes a discussion of those at risk for infection, the types of vaccines and the approaches for empirical and targeted antigen selection under development, as well as a perspective on where the field should go. In addition, the challenges in developing a vaccine for those individuals at risk are discussed.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available